Percheron Therapeutics Limited
ASX: PER.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- James Garner
- Employees
- 8
- Headquarters
- Melbourne, Australia
- IPO year
- 2023
- Market cap
- A$5.0M
- Website
- https://www.PercheronTx.com
Loading PER…
Loading profile data…Frequently asked questions about PER
What does Percheron Therapeutics Limited (PER.AX) do?
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, as...
Where does PER.AX trade?
Percheron Therapeutics Limited (PER.AX) trades on the Australian Securities Exchange.
What sector is PER.AX in?
Percheron Therapeutics Limited (PER.AX) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Percheron Therapeutics Limited?
James Garner is the chief executive officer of Percheron Therapeutics Limited (PER.AX).
Where is Percheron Therapeutics Limited headquartered?
Percheron Therapeutics Limited is headquartered in Australia.
Does PER.AX pay a dividend?
Percheron Therapeutics Limited (PER.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PER.AX go public?
Percheron Therapeutics Limited (PER.AX) completed its initial public offering in 2023.